Q3 Earnings Estimate for Galapagos Issued By Leerink Partnrs

Galapagos NV (NASDAQ:GLPG) – Equities research analysts at Leerink Partnrs raised their Q3 2025 EPS estimates for shares of Galapagos in a note issued to investors on Wednesday, July 23rd. Leerink Partnrs analyst F. Khurshid now forecasts that the biotechnology company will post earnings of ($0.77) per share for the quarter, up from their previous estimate of ($1.63). The consensus estimate for Galapagos’ current full-year earnings is ($1.60) per share. Leerink Partnrs also issued estimates for Galapagos’ Q4 2025 earnings at ($0.84) EPS, FY2025 earnings at ($6.23) EPS, Q1 2026 earnings at ($0.88) EPS, Q2 2026 earnings at ($0.91) EPS, Q3 2026 earnings at ($0.92) EPS, Q4 2026 earnings at ($0.94) EPS and FY2026 earnings at ($3.65) EPS.

Separately, Wall Street Zen raised shares of Galapagos from a “sell” rating to a “hold” rating in a report on Saturday. Four equities research analysts have rated the stock with a sell rating and five have given a hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $25.33.

Galapagos Stock Performance

Shares of NASDAQ:GLPG opened at $32.82 on Monday. The firm has a 50 day moving average of $29.30 and a 200-day moving average of $26.61. Galapagos has a 12 month low of $22.36 and a 12 month high of $33.86.

Institutional Investors Weigh In On Galapagos

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wealthquest Corp bought a new stake in shares of Galapagos during the 1st quarter valued at approximately $74,000. BNP Paribas Financial Markets grew its holdings in shares of Galapagos by 45.9% during the 4th quarter. BNP Paribas Financial Markets now owns 8,972 shares of the biotechnology company’s stock valued at $247,000 after purchasing an additional 2,824 shares during the last quarter. GAMMA Investing LLC grew its holdings in Galapagos by 354.5% during the 1st quarter. GAMMA Investing LLC now owns 10,148 shares of the biotechnology company’s stock worth $255,000 after acquiring an additional 7,915 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in Galapagos during the 2nd quarter worth approximately $261,000. Finally, Wealthedge Investment Advisors LLC bought a new stake in Galapagos during the 4th quarter worth approximately $311,000. 32.46% of the stock is owned by institutional investors.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.